Live Breaking News & Updates on Johna hohneker

Stay informed with the latest breaking news from Johna hohneker on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Johna hohneker and stay connected to the pulse of your community

Curis Appoints John A. Hohneker, M.D. To Board Of Directors

/PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today...

Evelo-biosciences , Burroughs-wellcome , Johna-hohneker , James-dentzer , Genentech , Gettysburg-college , Nasdaq , Novartis , Curis-inc , Therapeutics-inc , University-of-north-carolina-at-chapel-hill , Humanigen-inc

BioTheryX Announces Appointments of Three New Members to its Board of Directors

BioTheryX Announces Appointments of Three New Members to its Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New-york , United-states , Massachusetts , Northeastern-university , Burroughs-wellcome , Johna-hohneker , Diantha-duvall , David-stirling , Nancy-miller , Sarbanes-oxley , Linkedin , D-molecular-therapeutics-inc

BioTheryX Announces Appointments of Three New Members to its Board of Directors

BioTheryX Announces Appointments of Three New Members to its Board of Directors
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

New-york , United-states , Massachusetts , Northeastern-university , Burroughs-wellcome , Johna-hohneker , Diantha-duvall , David-stirling , Nancy-miller , Sarbanes-oxley , Linkedin , D-molecular-therapeutics-inc

BioTheryX Announces Appointments of Three New Members to its Board of Directors

BioTheryX Announces Appointments of Three New Members to its Board of Directors
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

New-york , United-states , Massachusetts , Northeastern-university , Burroughs-wellcome , Johna-hohneker , Diantha-duvall , David-stirling , Nancy-miller , Sarbanes-oxley , Linkedin , D-molecular-therapeutics-inc

BioSpace Movers & Shakers, May 21

Published: May 21, 2021
By Alex Keown
Biopharma and life sciences companies strengthen their leadership teams and board with these Movers & Shakers.
AavantiBio – Jessie Hanrahan was named chief regulatory officer of AavantiBio. Hanrahan will oversee global regulatory affairs for AavantiBio’s diversified pipeline of gene therapy programs targeting rare diseases with significant unmet medical needs. Most recently, she was Vice President of Regulatory Science at bluebird bio, Inc. Prior to bluebird bio, Hanrahan held positions of increasing responsibility at Genzyme Corp. where she worked across the oncology, multiple sclerosis and rare disease therapeutic areas. Earlier in her career, Hanrahan worked at Boston Scientific Corporation.

Colorado , United-states , Italy , Boston , Massachusetts , Milan , Lombardia , Oregon , Netherlands , America , Dutch , Stephen-basso

Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

Published: Mar 09, 2021
–Announced new positive data in human experimental model of inflammation of EDP1815–
–Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021–
–Initiated Phase 1b clinical trial of EDP1867 in atopic dermatitis; data expected in 4Q 2021–
–Up to 8 clinical data readouts expected over next 18 months–
–Management to host conference call at 8:30 a.m. ET–
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the fourth quarter and full year 2020.

Cambridge , Cambridgeshire , United-kingdom , Evelo-biosciences , Jessica-cotrone , Jonathan-zung , Johna-hohneker , John-hohneker , Development-expenses , Evelo-biosciences-inc , Rutgers-university , Linkedin

Evelo Biosciences, Inc.: Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights

(2)
-Announced new positive data in human experimental model of inflammation of EDP1815-
-Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021-
-Initiated Phase 1b clinical trial of EDP1867 in atopic dermatitis; data expected in 4Q 2021-
-Up to 8 clinical data readouts expected over next 18 months-
-Management to host conference call at 8:30 a.m. ET-
CAMBRIDGE, Mass., March 09, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today reported financial results and business highlights for the fourth quarter and full year 2020.

Cambridge , Cambridgeshire , United-kingdom , Evelo-biosciences , Jessica-cotrone , Jonathan-zung , Johna-hohneker , Kostenloser-wertpapierhandel , John-hohneker , Development-expenses , Evelo-biosciences-inc , Rutgers-university